☰
×
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
App
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Tremfya
PharmaShots Interview: Daphne Chan, Head of Dermatology Medical Affairs at Janssen Shares Insights on Clinical Study in Dermatolog...
July 26, 2022
Janssen Reports Results of Tremfya (guselkumab) in P-III Studies Demonstrated Durable Efficacy Across Joint and Axial Symptoms for...
June 1, 2022
Janssen Presents Results of Tremfya (guselkumab) in P-II (GALAXI 1) Trial and Long-Term Safety Profile for Stelara (ustekinumab) t...
May 25, 2022
Janssen Presents Results of Tremfya (guselkumab) in P-II (GALAXI 1) Clinical Trial for the Treatment of Active Crohn's Disease at...
February 22, 2022
Janssen Reports Results of Tremfya (guselkumab) in P-IIb (QUASAR) Induction Study for the Treatment of Active Ulcerative Colitis
February 21, 2022
PharmaShots Interview: Janssen’s Alyssa Johnsen Shares Insights on the New Clinical data of Tremfya (guselkumab) Presented at ACR...
January 4, 2022
Load more...
No more records!